The global metastatic castration-sensitive prostate cancer treatment market is experiencing significant development. This boom can be linked to factors such as an growing older population, escalating prevalence of prostate cancer, and advancements in treatment methods. The market is moreover driven by enhanced knowledge about the disease and its tr